The estimated Net Worth of Wendye Robbins is at least $296 mil dollars as of 14 March 2023. Ms. Robbins owns over 5,000 units of RAPT Therapeutics stock worth over $12,545 and over the last 5 years she sold RAPT stock worth over $0. In addition, she makes $283,251 as Independent Director at RAPT Therapeutics.
Sign up
Ms. Robbins RAPT stock SEC Form 4 insiders trading
Wendye has made over 16 trades of the RAPT Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 5,000 units of RAPT stock worth $97,600 on 14 March 2023.
The largest trade she's ever made was buying 7,000 units of RAPT Therapeutics stock on 10 May 2022 worth over $77,280. On average, Wendye trades about 947 units every 44 days since 2019. As of 14 March 2023 she still owns at least 6,500 units of RAPT Therapeutics stock.
You can see the complete history of Ms. Robbins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wendye Robbins biography
Wendye Robbins M.D. serves as Independent Director of the Company. She has served as President and CEO of Blade Therapeutics since August 2016 (and previously held the title of Interim CEO from May 2015 to July 2016). Dr. Robbins has also served as an independent consultant to venture investors in company formation and translational biology. Dr. Robbins has also served on the faculty at Stanford University School of Medicine in the Department of Anesthesia, Perioperative Care, and Pain Medicine since 2004. Dr. Robbins completed her residency in Anesthesiology at Johns Hopkins University School of Medicine, her internship in Internal Medicine at the University of Pennsylvania School of Medicine, and received her fellowship training in Pain Medicine from John Hopkins University School of Medicine. Dr. Robbins received an M.D. from The Medical College of Pennsylvania and a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley. Robbins’ extensive experience in the biopharmaceutical industry, her industry expertise and financial knowledge provide her with the qualifications and skills to serve as a director of our company.
What is the salary of Wendye Robbins?
As the Independent Director of RAPT Therapeutics, the total compensation of Wendye Robbins at RAPT Therapeutics is $283,251. There are 7 executives at RAPT Therapeutics getting paid more, with Rodney Young having the highest compensation of $2,296,220.
How old is Wendye Robbins?
Wendye Robbins is 59, she's been the Independent Director of RAPT Therapeutics since 2019. There are 5 older and 9 younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics, Inc. is Mary Gray, 67, who is the Independent Director.
What's Wendye Robbins's mailing address?
Wendye's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at RAPT Therapeutics
Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel, eFund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.
What does RAPT Therapeutics do?
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
What does RAPT Therapeutics's logo look like?
Complete history of Ms. Robbins stock trades at RAPT Therapeutics
RAPT Therapeutics executives and stock owners
RAPT Therapeutics executives and other stock owners filed with the SEC include:
-
Rodney Young,
Chief Financial Officer -
Brian Wong,
President, Chief Executive Officer, Director -
Dirk Brockstedt,
Chief Scientific Officer -
Dr. Brian Russell Wong M.D., Ph.D.,
CEO, Pres & Director -
Dr. William Ho,
Chief Medical Officer -
Dr. Dirk G. Brockstedt Ph.D.,
Chief Scientific Officer -
Mary Gray,
Independent Director -
Wendye Robbins,
Independent Director -
William Rieflin,
Independent Director -
Linda Kozick,
Independent Director -
Michael Giordano,
Independent Director -
Peter Svennilson,
Director -
William Ho,
Chief Medical Officer -
Lisa Moore,
Vice President - Business Development and Strategy -
Phyllis Gray,
Vice President of Human Resources -
Paul Kassner,
Senior Vice President - Quantitative and Computational Biology -
Dr. David Wustrow,
Sr. VP of Drug Discovery & Preclinical Devel. -
Dr. Paul Kassner,
Sr. VP of Quantitative & Computational Biology -
Steve Young Ph.D.,
VP of Technology -
Rodney K. B. Young,
CFO, Principal Accounting Officer & Sec. -
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Perkins Caufield & Byers Xv...,
-
David V Goeddel,
Director -
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Fund L.P.Topspin Biotech Fu...,
-
Karen C Lam,
VP, Finance and Controller -
Lori Lyons Williams,